Pharmacological therapies that block the effect of bradykinin or inhibit the activation of the kallikrein-kinin system, such as the ones approved for use in hereditary angioedema, represent potential novel treatments for the prevention of intradialytic hypotension. Here, KLK4 is linked to hereditary angioedema.